Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  G1 Therapeutics Inc    GTHX

G1 THERAPEUTICS INC

(GTHX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

G1 Therapeutics : to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2019 | 07:35am EDT

RESEARCH TRIANGLE PARK - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that additional findings from a Phase 2 clinical trial demonstrating the myelopreservation benefits of trilaciclib in 2nd/3rd-line small cell lung cancer (SCLC) patients will be featured as an oral presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

The presentation will take place on June 1, 2019 at 3:00 p.m. CT at the McCormick Place Convention Center in Chicago, Illinois.

Trilaciclib is a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy and improve patient outcomes.

'Chemotherapy remains an important treatment in the fight against cancer, however it has serious side effects, including damaging the patient's bone marrow. We are pleased to present further findings that show the addition of trilaciclib to chemotherapy can protect the bone marrow from damage in those undergoing treatment for SCLC,' said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. 'We look forward to our pre-NDA and pre-MAA meetings later this year with U.S. and European regulatory authorities as we work to bring trilaciclib to market for SCLC patients and continue to explore how trilaciclib may help those with other types of cancer.'

Details on the presentation are listed below and are also available on the 2019 ASCO Annual Meeting website: http://abstracts.asco.org/.

Title: Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.

Abstract Number: 8505

Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Date and Time: Saturday, June 1, 2019, 3:00-3:15 p.m. CT

Location: Hall D2, McCormick Place Lakeside Center Level 3

Presenter: Lowell Hart., M.D., Scientific Director of Research, Florida Cancer Specialists

About Trilaciclib

Trilaciclib is a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy and improve patient outcomes. G1 plans to submit marketing applications in the U.S. and Europefor trilaciclib for myelopreservation in SCLC in 2020. These submissions will be based on currently available data from three randomized, double-blind, placebo-controlled SCLC clinical trials, as well as safety data collected across all completed and ongoing clinical trials.

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib and lerociclib are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, lerociclib and G1T48 and the timing for next steps with regard to the trilaciclib marketing applications, and are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including the 'Risk Factors' sections contained therein and include, but are not limited to, the Company's ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the Company's initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; the Company's development of a CDK4/6 inhibitor to reduce chemotherapy-induced myelosuppression is novel, unproven and rapidly evolving and may never lead to a marketable product and market conditions. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Jeff Macdonald

Tel: 919-907-1944

Email: jmacdonald@g1therapeutics.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on G1 THERAPEUTICS INC
06/19G1 THERAPEUTICS : Announces Updated Results from Phase 2 Trial of Trilaciclib in..
AQ
06/18G1 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
06/18G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib i..
GL
06/14G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilacicli..
GL
06/14G1 THERAPEUTICS : Announces Updates to Board of Directors
AQ
06/13G1 THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of..
AQ
06/13G1 Therapeutics Announces Updates to Board of Directors
GL
06/12G1 THERAPEUTICS : to Present at Raymond James Life Sciences and MedTech Conferen..
AQ
06/11G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Confere..
GL
06/03G1 THERAPEUTICS : Presents Additional Phase 2 Data on Trilaciclib in Small Cell ..
AQ
More news
Financials ($)
Sales 2019 -
EBIT 2019 -116 M
Net income 2019 -112 M
Finance 2019 396 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 0
EV / Sales 2020 0
Capitalization 1 045 M
Chart G1 THERAPEUTICS INC
Duration : Period :
G1 Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends G1 THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 69,0 $
Spread / Average Target 147%
EPS Revisions
Managers
NameTitle
Mark A. Velleca President, Chief Executive Officer & Director
Seth A. Rudnick Chairman
Barclay A. Phillips CFO & Senior VP-Corporate Development
Jay C. Strum Chief Scientific Officer
Rajesh K. Malik Chief Medical Officer & Senior Vice President-R&D
Sector and Competitors
1st jan.Capitalization (M$)
G1 THERAPEUTICS INC41.83%747
GILEAD SCIENCES10.92%80 909
VERTEX PHARMACEUTICALS11.02%42 680
REGENERON PHARMACEUTICALS-14.29%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC19.01%8 523